Int Ophthalmol:视网膜中央静脉阻塞患者房水中lipocalin-2水平升高

2018-03-26 cuiguizhong MedSci原创

土耳其卡夫卡斯大学医学院眼科的Koban Y近日在Int Ophthalmol发表了一项重要的研究,他们对视网膜中央静脉阻塞(CRVO)患者的血清和房水中脂质运载蛋白-2(LCN2)的浓度进行了研究。

土耳其卡夫卡斯大学医学院眼科的Koban Y近日在Int Ophthalmol发表了一项重要的研究,他们对视网膜中央静脉阻塞(CRVO)患者的血清和房水中脂质运载蛋白-2(LCN2)的浓度进行了研究。

他们对16例白内障患者和16例同时患有视网膜中央静脉阻塞(CRVO)和黄斑水肿患者的血清和房水中LCN2的浓度进行了比较。在无菌条件下,在手术室中收集玻璃体内注射雷珠单抗后或白内障手术之前的样品。基于标准酶联免疫吸附测定技术,使用市售试剂盒(人脂质运载蛋白-2 / NGAL PicoKine ELISA试剂盒,MyBioSource Inc.,USA;目录号:MBS175829)测量血清和房水样品中的LCN2水平。

分析发现,CRVO组中,房水中LCN2浓度高于对照组(p = 0.021),但两组血清中LCN2水平没有显着差异(p = 0.463)。

因此,他们认为,在视网膜中央静脉阻塞(CRVO)患者的房水中LCN2的浓度会显着升高。 LCN2可能是促进分解代谢的一部分,可能在CRVO的并发症中起重要作用,例如导致失明的黄斑水肿、黄斑缺血和新血管形成等。

原文出处:

Koban, Y., et al., Elevated lipocalin-2 level in aqueous humor of patients with central retinal vein occlusion. Int Ophthalmol, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-11-07 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-07-04 smlt2008
  4. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-11-23 tomyang96
  5. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-03-30 紫迎馨

    关注

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-03-28 zutt
  7. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-03-28 dzx0922892
  8. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1697664, encodeId=9571169e66403, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Nov 07 18:20:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801539, encodeId=28c6180153944, content=<a href='/topic/show?id=89ac90e38c9' target=_blank style='color:#2F92EE;'>#视网膜中央静脉阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90738, encryptionId=89ac90e38c9, topicName=视网膜中央静脉阻塞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Dec 26 21:20:00 CST 2018, time=2018-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927923, encodeId=d9b7192e92369, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Jul 04 12:20:00 CST 2018, time=2018-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1696811, encodeId=c397169681123, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Fri Nov 23 06:20:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=301244, encodeId=cf6f3012449f, content=关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/11/eb1f237032e0bf07b10833fc3722e645.jpg, createdBy=2fed2145219, createdName=紫迎馨, createdTime=Fri Mar 30 19:55:06 CST 2018, time=2018-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1270031, encodeId=bcd012e003161, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510828, encodeId=0d27151082863, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541332, encodeId=5169154133293, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Mar 28 13:20:00 CST 2018, time=2018-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299995, encodeId=502f299995b7, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Mar 26 23:12:38 CST 2018, time=2018-03-26, status=1, ipAttribution=)]
    2018-03-26 orangesking

    0

相关资讯

Nat Commun:巧夺天工!复旦大学团队让失明小鼠重获视力

视网膜是一类重要的感光组织,能将光信号转变为神经信号,从而让大脑“看见”光。然而,一类叫做视网膜退行性疾病的顽疾却会让感光细胞出现不可逆的损伤,影响人的视力,甚至导致失明。目前,此类疾病还没有良好的治疗方法。

New Engl J Med:视网膜神经细胞再生疗法或可治疗严重眼疾

复旦大学附属眼耳鼻喉科医院眼科研究院院长卢奕教授与加州大学圣地亚哥分校张康教授团队携手,阐述在应用视网膜神经细胞重编程、再生疗法用于治疗严重眼部疾病研究方面取得重大进展,最新一期国际权威顶级期刊《新英格兰医学杂志》( 《NEJM杂志》 )刊发综述,对这项研究成果作了重点介绍。

FASEB J:CRY1和CRY2在哺乳动物视网膜时钟节律中的作用差异

英国牛津大学睡眠和昼夜节律神经科学研究所的Wong JCY近日在FASEB J发表了一项重要工作,他们研究了生物节律调节蛋白CRY1和CRY2在两种性别的小鼠视网膜中的表达和功能。

PLoS One:慢性双侧颈总动脉闭塞(BCCAO)小鼠模型中视网膜的个体和时间差异

德国柏林CharitéUniversittsmedizin大学眼科的Crespo-Garcia S近日在PLoS One发表了一份工作,他们使用小鼠双侧颈总动脉闭塞(BCCAO)的方法,建立的缺血性视网膜病模型,并进行多模式体内和离体的后续研究。

Retin Cases Brief Rep:POEMS综合征中的视网膜微结构

日本福岛医科大学医学部眼科的Tomita R近日在Retin Cases Brief Rep发表了一篇文章,报告了一名67岁女性患者,患有多发性神经病、器官肿大、内分泌病、单克隆丙种球蛋白病和皮肤病变(POEMS)综合征,显示双侧浆液性视网膜脱离。他们使用光学相干断层扫描和自适应光学(AO)相机,通过多模式成像技术来评估视网膜损伤情况。

Curr Eye Res:视网膜脱离和增殖性玻璃体视网膜病变中抗视网膜抗体的水平

日本仙台东北大学医学研究院眼科的Ichinohasama R近日在Curr Eye Res发表了一项工作,他们研究了眼内抗视网膜抗体与孔源性视网膜脱离(RRD)和增殖性玻璃体视网膜病变(PVR)患者的临床测量之间的相关性。